Recent Updates
Recently added Catalysts

Aggressive B-Cell Non-Hodgkin's Lymphoma: one US-listed biotech with a clinical-stage programme

OncologyUncontestedData as of 2026-09-04

Competitors1in the clinic
Median market cap$168Muniverse median $1.20B
Allocated capital$34M$168M competing
Phase 3 or filed01 mid, 0 early
Pure plays0this indication only
Capital rank294/299crowding rank 294

Aggressive B-Cell Non-Hodgkin's Lymphoma is uncontested. ADC Therapeutics (ADCT) is the only US-listed developer in the $100M to $20B band running a clinical programme here, with Loncastuximab Tesirine and Acalabrutinib in phase 2.

There is no public comparable to price it against. ADCT spreads its $168M market cap across 5 indications, so $34M of it is allocated here.

Nothing here has reached Phase 3: 1 programme in mid stage and 0 in early stage, so the field is still several years from a first approval.

$34M of allocated capital sits in Aggressive B-Cell Non-Hodgkin's Lymphoma, ranking it 294th of 299 indications by the money committed to it.

Companies developing drugs for Aggressive B-Cell Non-Hodgkin's Lymphoma 1

TickerCompanyLead assetPhaseTrialsMarket capPure playIndicationsNext catalyst
ADCTADC TherapeuticsLoncastuximab Tesirine and AcalabrutinibPhase 21$168MNo5 31 Dec 2026

Sorted by phase, then by market capitalisation. Ticker links open the company profile.

Why Aggressive B-Cell Non-Hodgkin's Lymphoma counts as uncontested

Uncontested. One US-listed developer in the size band is running a clinical programme here, so there is no public comparable to price it against.

The map splits indications on two folds: six or more competitors counts as crowded, and a median company above $1.20B counts as richly priced. Aggressive B-Cell Non-Hodgkin's Lymphoma has one competitor and a median of $168M.

Oncology

Oncology holds $187B of the map's capital, 27.8% of the total, spread across 119 indications and 103 companies. 34 of those indications have more than one company competing.

See every Oncology indication on the map

Related indications in Oncology

Follicular Lymphoma1 company · $34M · median $168MUncontestedPediatric Brain Tumor1 company · $41M · median $124MUncontestedMetastatic Anal Cancer1 company · $51M · median $102MUncontestedMetastatic Pancreatic Adenocarcinoma1 company · $53M · median $371MUncontestedNewly Diagnosed Glioblastoma1 company · $53M · median $371MUncontestedMetastatic Urothelial Cancer1 company · $54M · median $214MUncontestedRelapsed or Refractory Multiple Myeloma1 company · $13M · median $203MUncontestedAcute Lymphoblastic Leukemia1 company · $13M · median $203MUncontested

Aggressive B-Cell Non-Hodgkin's Lymphoma pipeline questions

Which biotech companies are developing drugs for Aggressive B-Cell Non-Hodgkin's Lymphoma?

ADC Therapeutics (ADCT, Loncastuximab Tesirine and Acalabrutinib, Phase 2). Those are the 1 US-listed developer in the $100M to $20B market cap band with a clinical-stage programme in Aggressive B-Cell Non-Hodgkin's Lymphoma.

How advanced is the Aggressive B-Cell Non-Hodgkin's Lymphoma pipeline?

Of the 1 clinical-stage programme in Aggressive B-Cell Non-Hodgkin's Lymphoma, 0 are in Phase 3 or filed, 1 is in mid-stage development and 0 are in early-stage development.

Is anyone else developing a drug for Aggressive B-Cell Non-Hodgkin's Lymphoma?

No. ADCT is the only US-listed company in the $100M to $20B market cap band with a clinical-stage programme in Aggressive B-Cell Non-Hodgkin's Lymphoma, which is why the indication is classified as uncontested.

When is the next Aggressive B-Cell Non-Hodgkin's Lymphoma catalyst?

The next dated catalyst in Aggressive B-Cell Non-Hodgkin's Lymphoma is ADCT on 31 Dec 2026. 1 dated event across the field fall in the next 12 months.

How this page is built

  • Universe is US-listed drug developers with a $100M to $20B market capitalisation, identified by SEC SIC code 2833, 2834 or 2836 or by a pharmaceutical or biotechnology industry classification, less a reviewed exclusion list of contract research organisations, device and diagnostics makers and diversified generics manufacturers.
  • An asset attributed to three or more different companies is treated as shared standard of care rather than any one company’s programme and excluded. Pembrolizumab alone appears under 21 tickers in raw trial data.
  • A programme counts only where at least one industry-sponsored trial supports it, so investigator-initiated academic studies of third-party drugs are excluded.

Allocated capital divides each company’s market capitalisation evenly across the indications it is running clinical programmes in, so every dollar of the universe is counted exactly once. Total market capitalisation competing counts a company in each of its indications and therefore sums to more than the universe.

Third-party market size estimates are not used anywhere on this page. Approved incumbents are excluded from competitor counts, and companies above $20B are outside the universe by construction.

Back to the disease map